The minimally invasive vertebral compression fracture (VCF) device market, which has faced controversy and reduced procedure volumes in recent years due to concerns about efficacy and cost, is still a substantial and evolving US market, valued at $426 million in 2012, according to the latest estimates from Medtech Insight. A number of players boast FDA approvals and/or active vertebroplasty and vertebral augmentation product development programs, including Benvenue Medical Inc., CareFusion Corp., Crosstrees Medical Inc., DFINE Inc., market leader Medtronic PLC, Osseon Therapeutics Inc., NeuroTherm Inc., Sintea Plustek SRL, Soteira Inc., Spine Wave Inc., and Stryker Corp.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?